Expression of HIF-2&alpha;/EPAS1 in hepatocellular carcinoma

doi:10.3748/wjg.v10.i4.525

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3228)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

339

HTML

2613

Figures (1-2)

147

Tables (1-3)

129

Sum=3228

Feb 15, 2004 (publication date) through May 24, 2024

Times Cited of This Article

Times Cited (33)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Feb 15, 2004; 10(4): 525-530
Published online Feb 15, 2004. doi: 10.3748/wjg.v10.i4.525

Expression of HIF-2α/EPAS1 in hepatocellular carcinoma

Gassimou Bangoura, Lian-Yue Yang, Gen-Wen Huang, Wei Wang

Gassimou Bangoura, Lian-Yue Yang, Gen-We Huang, Wei-Wang, Department of General Surgery and Liver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China

Author contributions: All authors contributed equally to the work.

Supported by the National Key Technologies R and D Program, No. 2001BA703B04

Correspondence to: Professor Lian-Yue Yang, Department of General Surgery and Liver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China. lianyueyang@hotmail.com

Telephone: +86-731-4327326 Fax: +86-731-4327232

Received: June 16, 2003
Revised: August 23, 2003
Accepted: October 7, 2003
Published online: February 15, 2004

Abstract

AIM: To investigate the expression of hypoxia-inducible factor (HIF)-2α/endothelial PAS domain protein1 (EPAS1) in hepatocellular carcinoma (HCC).

METHODS: Expression of HIF-2α/EPAS1 was investigated immunohistochemically on paraffin-embedded sections from 97 patients with HCC. To further confirm that HIF-2α/EPAS1 in HCC tissues also correlated with angiogenesis, a parallel immunohistchemistry study of vascular endothelial growth factor (VEGF) was performed on these 97 cases.

RESULTS: HIF-2α/EPAS1 could be detected in 50 of 97 cases (51.6%), including 19 weakly positive (19.8%), and 31 strongly positive (31.1%), the other 47 cases were negative (48.4%). The expression of HIF-2α/EPAS1was significantly correlated with tumor size, capsule infiltration, portal vein invasion, and necrosis. A parallel immunohistochemical analysis of VEGF demonstrated its positive correlation with capsule infiltration, portal vein invasion, and HIF-2α/EPAS1 overexpression, which supported the correlation of HIF-2α/ EPAS1up-regulation with tumor angiogenesis. No apparent correlation was observed between HIF-2α/EPAS1 and capsular formation, presence of cirrhosis, and histological grade.

CONCLUSION: HIF-2α/EPAS1 is expressed in most of HCC with capsular infiltration and portal vein invasion, which indicates a possible role of HIF-2α/EPAS1 in HCC metastasis.

Keywords: $[Keywords]